GN
Therapeutic Areas
Dexcom Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Dexcom G7 Platform | Type 1, Type 2, Gestational Diabetes | Commercial |
| Stelo Glucose Biosensor | Metabolic Health / Non-Insulin Using Adults | Commercial |
| Next-Gen Sensor Development | Diabetes & Metabolic Health | R&D |
| Software & Algorithm Enhancements | All CGM Users | Continuous Development |
Leadership Team at Dexcom
JL
Jacob Leach
President & Chief Executive Officer
DA
Donald Abbey
EVP, Global Business Services, Regulatory, Medical and Clinical Affairs
MB
Michael Brown
EVP, Chief Legal Officer
JC
Jon Coleman
EVP, Chief Commercial Officer
MD
Matthew Dolan
EVP, Strategy & Corporate Development
SS
Sadie Stern
EVP, Chief Human Resources Officer
JS
Jereme Sylvain
EVP, Chief Financial Officer
KS
Kevin Sayer
Chair of the Board of Directors